Diprobase

Mineral Oil:

• Drug facts
• Active ingredients
• Purposes
• Uses
• Warnings
• Directions
• Other information
• Inactive ingredients
• Questions or comments?
• Diprobase (Mineral Oil) reviews

DRUG FACTS

ACTIVE INGREDIENTS

Diprobase (Mineral Oil) oil 14%

Petrolatum 74.9%

Phenylephrine HCl 0.25%

PURPOSES

Protectant

Protectant

Vasoconstrictor

USES

• helps relieve the local itching and discomfort associated with hemorrhoids
• temporarily shrinks hemorrhoidal tissue and relieves burning
• temporarily provides a coating for relief of anorectal discomforts
• temporarily protects the inflamed, irritated anorectal surface to help make bowel movements less painful

WARNINGS

For external and/or intrarectal use only

Ask a doctor before use if you have

• heart disease
• high blood pressure
• thyroid disease
• diabetes
• difficulty in urination due to enlargement of the prostate gland

Ask a doctor or pharmacist before use if you are

presently taking a prescription drug for high blood pressure or depression.

When using this product

do not exceed the recommended daily dosage unless directed by a doctor.

Stop use and ask a doctor if

• bleeding occurs
• condition worsens or does not improve within 7 days
• introduction of applicator into the rectum causes additional pain

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away.

DIRECTIONS

• adults: when practical, cleanse the affected area by patting or blotting with an appropriate cleansing wipe. Gently dry by patting or blotting with a tissue or a soft cloth before applying ointment.
• when first opening the tube, puncture foil seal with top end of cap
• apply to the affected area up to 4 times daily, especially at night, in the morning or after each bowel movement
• intrarectal use:
  • remove cover from applicator, attach applicator to tube, lubricate applicator well and gently insert applicator into the rectum
  • thoroughly cleanse applicator after each use and replace cover
• also apply ointment to external area
• regular use provides continual therapy for relief of symptoms
• children under 12 years of age: ask a doctor

OTHER INFORMATION

store at 20-25°C (68-77°F)

INACTIVE INGREDIENTS

benzoic acid, butylated hydroxyanisole, corn oil, glycerin, lanolin, lanolin alcohols, methylparaben, Diprobase (Mineral Oil) oil, paraffin, propylparaben, purified water, thymus vulgaris (thyme) flower/leaf oil, tocopherols excipient, white wax

QUESTIONS OR COMMENTS?

Call weekdays 9 AM to 5 PM EST at 1-800-99PrepH or 1-800-997-7374.

THIS PACKAGE CONTAINS AN OUTER CARTON. DO NOT BUY IF OUTER CARTON IS MISSING.

Diprobase (Mineral Oil)^®

HEMORRHOIDAL OINTMENT

Prevents Further

Irritation

• Prompt, Soothing Relief from Painful
  

  Burning, Itching and Discomfort

• Shrinks Swollen Hemorrhoidal Tissue
• Protects Irritated Tissue
• Relieves Internal and External Discomfort

NET WT 1 OZ (28 g)

Petrolatum White:

• Active ingredients
• Purpose
• Warnings
• Directions
• Inactive ingredients
• Diprobase (Petrolatum White) reviews

Active Ingredients

Dimethicone 20%

Petrolatum 25%

Purpose

Skin Protectant

Warnings

- Do not use over deep or puncture wounds, infections, or lacerations. For external use only.

- When using this product do not get into eyes. If contact occurs, rinse eyes throughout with water.

- Stop use and ask a doctor if condition worsens or does not improve with 7 days.

Directions

- Change wet and soiled diapers promptly, cleanse the diaper area, and allow to dry.

- Shake bottle well before use.

- Spray 4-6 inches from skin. No rub-in is required.

- Apply liberally as often as necessary, with each diaper change, and especially at bedtime or anytime exposure to we diapers is prolonged.

Inactive Ingredients

Cyclomethicone, Hexamethyldisiloxane, Lanolin, Light Mineral Oil, Microcrystalline Wax, Vitamin A Palmitate, Vitamin D3, Water

Uses: Protects minor skin irritation due to diaper rash and helps seal out wetness.

- Keep out of reach of children. If swallowed, get medical help or contact a local poison control center immediately.

Enter section text here

RRCL

Sodium Phosphate Monobasic Monohydrate:

• Indications and usage
• Contraindications
• Warnings
• Precautions
• Adverse reactions
• Overdosage
• Dosage and administration
• How supplied
• Diprobase (Sodium Phosphate Monobasic Monohydrate) reviews

INDICATIONS AND USAGE

Sodium Phosphates Injection, USP is indicated as a source of phosphate, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions.

CONTRAINDICATIONS

Sodium phosphate is contraindicated in diseases where high phosphate or low calcium levels may be encountered, and in patients with hypernatremia.

WARNINGS

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

Sodium Phosphates Injection must be diluted and thoroughly mixed before use.

To avoid phosphate intoxication, infuse solutions containing sodium phosphate slowly. Infusing high concentrations of phosphate may result in a reduction of serum calcium and symptoms of hypocalcemic tetany. Calcium levels should be monitored.

Solutions containing sodium ion should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.

In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.

PRECAUTIONS

General

Use with caution in patients with renal impairment, cirrhosis, cardiac failure or in conjunction with other edematous medications. It should not be used with sodium-retaining medications.

Caution must be exercised in the administration of parenteral fluids especially those containing sodium ion, to patients receiving corticosteroids or corticotropin.

Laboratory Tests

Phosphate replacement therapy with sodium phosphate should be guided primarily by serum inorganic phosphate levels and the limits imposed by the accompanying sodium ion. Frequent monitoring of serum calcium and sodium as well as renal function is recommended.

Drug Interactions

Concurrent use with thiazides may cause renal damage.

Pregnancy Category C

Animal reproduction studies have not been conducted with sodium phosphate. It is also not known whether sodium phosphate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium phosphate should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sodium phosphate is administered to a nursing woman.

Geriatric Use

An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Sodium ions and phosphorus ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

ADVERSE REACTIONS

Adverse reactions involve the possibility of phosphate intoxication. Phosphate intoxication results in a reduction of serum calcium and the symptoms are those of hypocalcemic tetany (see WARNINGS ).

OVERDOSAGE

In the event of overdosage, discontinue infusions containing sodium phosphate immediately and institute corrective therapy to restore depressed serum calcium and to reduce elevated serum sodium levels. (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS )

DOSAGE AND ADMINISTRATION

Sodium Phosphates Injection is administered intravenously only after dilution and thorough mixing in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of millimoles of phosphate and milliequivalents of sodium.

In patients on TPN, approximately 10 to 15 mmol of phosphorus (equivalent to 310 to 465 mg elemental phosphorus) per liter bottle of TPN solution is usually adequate to maintain normal serum phosphate, though larger amounts may be required in hypermetabolic states. The amount of sodium which accompanies the addition of phosphate also should be kept in mind, and if necessary, serum sodium levels should be monitored.

The suggested dose of phosphorus for infants receiving TPN is 1.5 to 2 mmol/kg/day.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

Product No.	NDC No.	Volume
17005PX	63323-170-05	5 mL in a 10 mL vial
17015PX	63323-170-15	15 mL in a 30 mL vial
11850	63323-118-50	50 mL in a 50 mL vial

These vials are flip-top, Single Dose Vials, packaged 25 vials per tray. The vials marked with ‘‘PX’’ are partially filled to facilitate transfer of the contents.

Do not administer unless solution is clear and seal intact. Discard unused portion.

Store at 20° to 25°C (68° to 77°F).

45780G

Revised: August 2017

logo

PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Sodium Phosphates 15 mL Single Dose Vial Label

NDC 63323-170-15

17015PX

Sodium Phosphates Injection, USP

Phosphorus 45 mmol / 15 mL (3 mmol/mL)

Sodium 60 mEQ / 15 mL (4 mEq/mL)

Must Be Diluted Prior to IV Use

15 mL Single Dose Vial

Rx only

vial